Targeting myostatin for therapies against muscle-wasting disorders

Research output: Contribution to journalReview article

76 Citations (Scopus)

Abstract

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary approaches to drug discovery and development offer promising therapeutic strategies for intractable genetic muscular disorders including muscular dystrophy. Inhibition of the production and activity of myostatin, a potent growth factor that determines skeletal muscle size, is a novel strategy for the treatment of muscle-wasting disorders such as muscular dystrophy, cachexia and sarcopenia. Myostatin blockers include myostatin-blocking antibodies, myostatin propeptide, follistatin and follistatin-related proteins, soluble myostatin receptors, small interfering RNA and small chemical inhibitors. This review describes the discovery and development of myostatin inhibitors.

Original languageEnglish
Pages (from-to)487-494
Number of pages8
JournalCurrent Opinion in Drug Discovery and Development
Volume11
Issue number4
Publication statusPublished - 01-07-2008

Fingerprint

Myostatin
Muscular Diseases
Muscular Dystrophies
Follistatin-Related Proteins
Therapeutics
Follistatin
Sarcopenia
Cachexia
Inborn Genetic Diseases
Blocking Antibodies
Cell Transplantation
Drug Discovery
Genetic Therapy
Small Interfering RNA
Intercellular Signaling Peptides and Proteins
Skeletal Muscle

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

@article{2e1a7117a5f645a6900ddde51d5913c8,
title = "Targeting myostatin for therapies against muscle-wasting disorders",
abstract = "In addition to gene correction therapy and cell transplantation techniques, multidisciplinary approaches to drug discovery and development offer promising therapeutic strategies for intractable genetic muscular disorders including muscular dystrophy. Inhibition of the production and activity of myostatin, a potent growth factor that determines skeletal muscle size, is a novel strategy for the treatment of muscle-wasting disorders such as muscular dystrophy, cachexia and sarcopenia. Myostatin blockers include myostatin-blocking antibodies, myostatin propeptide, follistatin and follistatin-related proteins, soluble myostatin receptors, small interfering RNA and small chemical inhibitors. This review describes the discovery and development of myostatin inhibitors.",
author = "K. Tsuchida",
year = "2008",
month = "7",
day = "1",
language = "English",
volume = "11",
pages = "487--494",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "4",

}

Targeting myostatin for therapies against muscle-wasting disorders. / Tsuchida, K.

In: Current Opinion in Drug Discovery and Development, Vol. 11, No. 4, 01.07.2008, p. 487-494.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting myostatin for therapies against muscle-wasting disorders

AU - Tsuchida, K.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - In addition to gene correction therapy and cell transplantation techniques, multidisciplinary approaches to drug discovery and development offer promising therapeutic strategies for intractable genetic muscular disorders including muscular dystrophy. Inhibition of the production and activity of myostatin, a potent growth factor that determines skeletal muscle size, is a novel strategy for the treatment of muscle-wasting disorders such as muscular dystrophy, cachexia and sarcopenia. Myostatin blockers include myostatin-blocking antibodies, myostatin propeptide, follistatin and follistatin-related proteins, soluble myostatin receptors, small interfering RNA and small chemical inhibitors. This review describes the discovery and development of myostatin inhibitors.

AB - In addition to gene correction therapy and cell transplantation techniques, multidisciplinary approaches to drug discovery and development offer promising therapeutic strategies for intractable genetic muscular disorders including muscular dystrophy. Inhibition of the production and activity of myostatin, a potent growth factor that determines skeletal muscle size, is a novel strategy for the treatment of muscle-wasting disorders such as muscular dystrophy, cachexia and sarcopenia. Myostatin blockers include myostatin-blocking antibodies, myostatin propeptide, follistatin and follistatin-related proteins, soluble myostatin receptors, small interfering RNA and small chemical inhibitors. This review describes the discovery and development of myostatin inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=46749087409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749087409&partnerID=8YFLogxK

M3 - Review article

C2 - 18600566

AN - SCOPUS:46749087409

VL - 11

SP - 487

EP - 494

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 4

ER -